Evidence map›Paper›PMID 38893542›Full record

ReviewMolecules (Basel, Switzerland)2024

Imidazopyridine Family: Versatile and Promising Heterocyclic Skeletons for Different Applications.

Giorgio Volpi, Enzo Laurenti, Roberto Rabezzana

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Graphitic Carbon Nitride (g-CMolecules (Basel, Switzerland) · 2026
    Review
  3. Article
  4. Article
  5. Imidazo[1,2‑ACS omega · 2026
    Review
  6. Article
  7. Synthesis of imidazopyridinesRSC advances · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Giorgio VolpiDepartment of Chemistry, University of Turin, Via Pietro Giuria 7, 10125 Torino, Italy.ORCID 0000-0002-9695-9202
Enzo LaurentiDepartment of Chemistry, University of Turin, Via Pietro Giuria 7, 10125 Torino, Italy.ORCID 0000-0001-7363-4002
Roberto RabezzanaDepartment of Chemistry, University of Turin, Via Pietro Giuria 7, 10125 Torino, Italy.ORCID 0000-0003-0699-0597

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, there has been increasing attention focused on various products belonging to the imidazopyridine family; this class of heterocyclic compounds shows unique chemical structure, versatile optical properties, and diverse biological attributes. The broad family of imidazopyridines encompasses different heterocycles, each with its own specific properties and distinct characteristics, making all of them promising for various application fields. In general, this useful category of aromatic heterocycles holds significant promise across various research domains, spanning from material science to pharmaceuticals. The various cores belonging to the imidazopyridine family exhibit unique properties, such as serving as emitters in imaging, ligands for transition metals, showing reversible electrochemical properties, and demonstrating biological activity. Recently, numerous noteworthy advancements have emerged in different technological fields, including optoelectronic devices, sensors, energy conversion, medical applications, and shining emitters for imaging and microscopy. This review intends to provide a state-of-the-art overview of this framework from 1955 to the present day, unveiling different aspects of various applications. This extensive literature survey may guide chemists and researchers in the quest for novel imidazopyridine compounds with enhanced properties and efficiency in different uses.

Indexed as

imidazo[1,2-a]pyridinesimidazo[1,5-a]pyridinesimidazo[2,1-a]isoquinolines heterocycleimidazo[4,5-c]pyridinesimidazo[5,1-a]quinolonesimidazoisoquinolineimidazopyridine

Identifiers

PMID38893542
PMCPMC11173518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.